Thomas Falconer

Thomas Falconer is a Programmer Analyst at Columbia University, where he contributes to large-scale, real-world evidence research in clinical epidemiology and health sciences. His work focuses on the comparative safety and effectiveness of glucose-lowering therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, using observational data and network studies such as LEGEND-T2DM. His recent publications examine cardiovascular outcomes, thyroid tumor risk, and ophthalmologic adverse events like nonarteritic anterior ischemic optic neuropathy, alongside methodological advances in Alzheimer's disease prediction. His research integrates statistics, pharmacology, and respiratory medicine to inform clinical decision-making.